Article From: "Allison DeAngelis"   Read full article

Selecta Biosciences has announced plans to cut more than a third of its employees and shelve a cancer drug following various trial problems late last year.

The Watertown biotech said it will eliminate 36 percent of its staff positions as part of a company restructuring. Selecta (Nasdaq: SELB) had 64 full-time employees as of January 2018, according to a federal filing.

Selecta is also reshuffling its drug pipeline, dropping a cancer drug that was linked to a patient death in an early stage trial…